ST266 Versus Standard Care In Treating Partial Thickness Burns

Burns Clinical Trial

Official title:

Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00886470
• Other study ID #: ACCS-PT-09.001
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: June 2009
• Est. completion date: March 2010

Study information

• Verified date: May 2019
• Source: Noveome Biotherapeutics, formerly Stemnion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this protocol is to perform a safety and dose-determination efficacy clinical trial in patients having a degree of partial-thickness burn wounds. The trial will be a prospectively randomized and double-blind trial of ST266 compared with standardized care using 0.9% NaCl (normal saline) solution in the same three treatment regimens.

Description:

A Phase I/II multi-center clinical trial will be performed in 99 adults with partial-thickness burns. Two similar partial-thickness burn areas in a single patient will be selected. One burn will be randomly assigned to receive either test drug ST266 or normal saline in one of three treatment regimens.

The three treatment arms will be:

1. ST266 0.01 mL/cm2 every 7th day vs. normal saline 0.01 mL/cm2 every 7th day;

2. ST266 0.01 mL/cm2 every 4th day vs. normal saline 0.01 mL/cm2 every 4th day; and

3. ST266 0.01 mL/cm2 every other day vs. normal saline 0.01 mL/cm2 every other day.

Two different preclinical studies of partial-thickness burns on guinea pigs have demonstrated accelerated epithelialization with topical treatment with ST266. Similarly, preclinical studies in Yorkshire pigs have demonstrated more rapid maturity of epithelialization and better quality healing of partial-thickness skin graft donor sites with ST266 treatment.

In the preclinical studies, ST266 given in a dose of 0.01 mL/cm2 wound area appeared to saturate the wound adequately without excess and simultaneously improve healing. In preclinical toxicity studies, the dose of 0.01 mL/cm2 was shown to be safe.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• A signed IRB (Institutional Review Board)- approved Informed Consent Form;

• 18 - 65 years of age;

• Two (2) similar, non-contiguous, partial-thickness burn wounds between 50 cm2 and 250 cm2 in area with blisters removed in a Total Body Surface Area(TBSA) burn of less than or equal to 40% TBSA;

• Burns must be thermal burns of flame or scald etiology;

• Patient must present to the burn center within 8 hours of injury;

• Normal creatinine and bilirubin levels;

• If capable of bearing children, patient must be using a medically accepted means of birth control and have a negative serum pregnancy test;

• Willing to participate in the clinical study and comply with the requirements of the trial.

Exclusion Criteria:

• The two (2) chosen wounds must not be full-thickness (extending through the dermis into the subcutaneous tissue);

• Thermal burn from chemical, electrical or radiation causes;

• Neither the study wound nor the comparator wound can be < 50 cm2 or >250 cm2 in size and cannot be on the face or hands;

• Patients with significant pulmonary injury, i.e., smoke inhalation injury requiring ventilator support;

• Patients with diabetes;

• Patients with any immune deficiency including current treatment with corticosteroid medication, chemotherapeutic agents, anti-viral therapy, or concurrent radiation therapy within 30 days of signing the informed consent;

• Abnormal bilirubin, liver function studies (i.e., Alanine transaminase (ALT); Aspartate transaminase (AST)> 2.0 times normal);

• Abnormal serum creatinine, receiving hemodialysis or peritoneal dialysis;

• Active cancer or a history of cancer in the 5 years prior to signing the informed consent form (history of basal cell carcinoma is allowed);

• Psychiatric condition or substance abuse which in the Investigator's opinion may pose a threat to patient compliance;

• History of non-compliance with treatment or clinical visit attendance.

• Patients whose burns were previously treated with anything other than ice, cold water or dry dressing.

• Participation in an investigational trial within 30 days of study entry.

Related Conditions & MeSH terms

• Burns

Intervention

Biological:
• ST266
ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.

Locations

Country	Name	City	State
United States	Johns Hopkins Burn Center	Baltimore	Maryland
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	MetroHealth Medical Center	Cleveland	Ohio
United States	University of Missouri Health Care	Columbia	Missouri
United States	Shands Burn Center at the University of Florida	Gainesville	Florida
United States	John S. Dunn Sr. Burn Center	Houston	Texas
United States	University of Kentucky Chandler Medical Center	Lexington	Kentucky
United States	LAC - USC Medical Center	Los Angeles	California
United States	Loyola University Medical Center	Maywood	Illinois
United States	University of South Alabama Dept. of Surgery	Mobile	Alabama
United States	Western Pennsylvania Hospital	Pittsburgh	Pennsylvania
United States	University of Rochester	Rochester	New York
United States	Acute & Critical Care Surgery Barnes Jewish Hospital, Washington University Medical Center	Saint Louis	Missouri
United States	University of South Florida / Tampa General Hospital	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Noveome Biotherapeutics, formerly Stemnion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint will be the percentage of each wound that has epithelialized during the 21-day treatment period comparing the ST266-treated wound with the saline-treated wound.		21 days
Secondary	The number of totally epithelialized (100%) wounds in the ST266-treated wounds versus the number in the normal saline-treated wounds		21 days
Secondary	The percentage conversion to full-thickness wounds in the ST266-treated wounds versus the conversion in the normal saline-treated wounds		21 days
Secondary	Quality of healing, including pruritis, and scar hypertrophy, and reduction in pain in the ST266-treated wounds as compared to saline-treated wounds		21 days
Secondary	Quality of healing as assessed by hemoxylin and eosin staining of the punch biopsy taken on Day 21 in the ST266-treated wounds as compared to saline-treated wounds		21 days
Secondary	Assessment of change in arterial circulation using a laser Doppler from baseline to Day 21 in the ST266-treated wounds as compared to saline-treated wounds		21 days
Secondary	Determination of levels of 6 cytokines present in blood prior to treatment (baseline) and within one-hour of the first treatment for the initial 12 patients		21 days
Secondary	The primary safety endpoint will be the incidence of adverse events post-treatment.		12 months